Living Cell Technologies Company Announcement

Living Cell Technologies Company Announcement

Living Cell Technologies highlights its internationally leading technology at a meeting on Stem Cells and Cell Programming

2 September 2009: Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) is presenting highlights of its neonatal pig cell technologies at an international meeting on Stem Cells and Cellular Programming on Thursday, 3 September in Queenstown, New Zealand.

Dr Paul Tan, LCT CEO, who is delivering the invited lecture says: “Immature cells contained in the pancreas of piglets are capable of growing rapidly and maturing into long lived insulin producing cells. Unlike stem cells they do not develop into tumours.”

LCT’s lead product for insulin dependent type 1 diabetes, DIABECELL®, uses neonatal porcine islets which are encapsulated to prevent rejection.

The presentation also highlights LCT’s NeurotrophinCell (NTCELL) which can be used to encourage progenitor cells naturally present in the brain to repair brain tissue damaged by a variety of noxious influences. The reparative effect results from brain growth and support factors known as neurotrophins released by the porcine choroid plexus cells encapsulated within NTCELL.

LCT has published and presented data showing that in animal models of hearing loss, Parkinson’s disease, Huntington’s disease and stroke, implants of NTCELL nerve or brain tissue and lead to recovery of hearing or the use and function of limbs respectively.

Both DIABECELL® and NTCELL are LCT products that are encapsulated in a gel to prevent rejection by the immune system.

NeurotrophinCell:

Brain choroid plexus cells

producing reparative hormones

in gel capsules

 
ends